(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Unwinding History's Secrets: Looking for the Response to Antiquated Human advancements - 2Top 20 Compelling Business Books for Progress
- 3US FDA unveils new pathway to approve personalized therapies
- 4From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- 5Elite Execution Wall televisions for Film Darlings
- Ukraine proved this drone-killer works. Now, the West is giving it a shot.
- Well known Tea Brands for Each Tea Sweetheart
- Go on A Careful spending plan: Modest Objections for Your List of must-dos
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- 4 Family SUVs: Joining Solace and Style
- A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- 5 Indoor Plants That Further develop Air Quality
- The 10 Most Significant Virtual Entertainment Missions
- Find the Lively Food Markets of South America
